Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science

Autor: Diane Stephenson, Robert Alexander, Varun Aggarwal, Reham Badawy, Lisa Bain, Roopal Bhatnagar, Bastiaan R. Bloem, Babak Boroojerdi, Jackson Burton, Jesse M. Cedarbaum, Josh Cosman, David T. Dexter, Marissa Dockendorf, E. Ray Dorsey, Ariel V. Dowling, Luc J. W. Evers, Katherine Fisher, Mark Frasier, Luis Garcia-Gancedo, Jennifer C. Goldsack, Derek Hill, Janice Hitchcock, Michele T. Hu, Michael P. Lawton, Susan J. Lee, Michael Lindemann, Ken Marek, Nitin Mehrotra, Marjan J. Meinders, Michael Minchik, Lauren Oliva, Klaus Romero, George Roussos, Robert Rubens, Sakshi Sadar, Joseph Scheeren, Eiichi Sengoku, Tanya Simuni, Glenn Stebbins, Kirsten I. Taylor, Beatrice Yang, Neta Zach

Publikováno v: Digital Biomarkers, Vol 4, Iss 1, Pp 28-49 (2020)

Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disease continuu

Externí odkaz: https://doaj.org/article/02833b80db5e4df4916766e3401c1666

MIDAS: Multi-device Integrated Dynamic Activity Spaces

Autor: Karadkar, Unmil Purushottam

Mobile phones, tablet computers, laptops, desktops, and large screen displays are increasingly available to individuals for information access, often simultaneously. Dominant content access protocols, such as HTTP/1.1, do not take advantage of this d

Externí odkaz: http://hdl.handle.net/1969.1/ETD-TAMU-2011-12-10428

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.

Autor: Stephenson D; Critical Path Institute, Tucson, Arizona, USA., Alexander R; Takeda, Cambridge, Massachusetts, USA., Aggarwal V; Critical Path Institute, Tucson, Arizona, USA., Badawy R; University of Birmingham, Birmingham, United Kingdom., Bain L; Independent Medical Writer, Philadelphia, Pennsylvania, USA., Bhatnagar R; Critical Path Institute, Tucson, Arizona, USA., Bloem BR; Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands., Boroojerdi B; UCB Biopharma, Brussels, Belgium., Burton J; Critical Path Institute, Tucson, Arizona, USA., Cedarbaum JM; Critical Path Institute, Tucson, Arizona, USA.; Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USA., Cosman J; Biogen, Cambridge, Massachusetts, USA.; AbbVie, Chicago, Illinois, USA., Dexter DT; Parkinson's UK, London, United Kingdom., Dockendorf M; Merck & Co. (MSD), Kenilworth, New Jersey, USA., Dorsey ER; University of Rochester, Rochester, New York, USA., Dowling AV; Takeda, Cambridge, Massachusetts, USA., Evers LJW; Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands., Fisher K; Biogen, Cambridge, Massachusetts, USA., Frasier M; Michael J. Fox Foundation, New York, New York, USA., Garcia-Gancedo L; GlaxoSmithKline, Stevenage, United Kingdom., Goldsack JC; Digital Medicine Society, Boston, Massachusetts, USA., Hill D; Critical Path Institute, Tucson, Arizona, USA., Hitchcock J; Critical Path Institute, Tucson, Arizona, USA., Hu MT; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom., Lawton MP; Critical Path Institute, Tucson, Arizona, USA., Lee SJ; Merck & Co. (MSD), Kenilworth, New Jersey, USA., Lindemann M; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Marek K; Institute of Neurodegenerative Diseases, New Haven, Connecticut, USA., Mehrotra N; Merck & Co. (MSD), Kenilworth, New Jersey, USA., Meinders MJ; Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Nijmegen, The Netherlands., Minchik M; Critical Path Institute, Tucson, Arizona, USA., Oliva L; Biogen, Cambridge, Massachusetts, USA., Romero K; Critical Path Institute, Tucson, Arizona, USA., Roussos G; Critical Path Institute, Tucson, Arizona, USA.; Birbeck College, University of London, London, United Kingdom., Rubens R; Takeda, Cambridge, Massachusetts, USA., Sadar S; Critical Path Institute, Tucson, Arizona, USA., Scheeren J; Critical Path Institute, Tucson, Arizona, USA., Sengoku E; UCB Biopharma, Brussels, Belgium., Simuni T; Northwestern University, Evanston, Illinois, USA., Stebbins G; Rush University, Chicago, Illinois, USA., Taylor KI; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; University of Basel, Basel, Switzerland., Yang B; Lundbeck, Copenhagen, Denmark., Zach N; Takeda, Cambridge, Massachusetts, USA.

Publikováno v: Digital biomarkers [Digit Biomark] 2020 Nov 26; Vol. 4 (Suppl 1), pp. 28-49. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020).